Poly Medicure Limited reported its financial results for the quarter and year ended March 31, 2026. The company achieved a consolidated annual revenue of Rs. 1,875.3 crore, representing a 12.3% growth over the previous year. Despite a challenging external environment and the impact of recent acquisitions, the company maintained a healthy operating EBITDA margin of 24.4% for FY26. The firm continues to focus on product innovation, expanding its global footprint, and high-end technology segments.
Annual Financial Performance Highlights
For the financial year 2026, Poly Medicure Limited reported a strong consolidated revenue of Rs. 1,875.3 crore, reflecting a 12.3% YoY growth. The consolidated gross profit reached Rs. 1,278.4 crore, with a robust gross profit margin of 68.1%. The operating EBITDA for the full year stood at Rs. 457.7 crore. Notably, the standalone performance showcased an EBITDA margin of 26.8%, placing it at the higher end of the company’s initial guidance range of 25%-27%.
Strategic Growth and Acquisitions
FY26 marked a pivotal year for inorganic growth, with the consolidation of PendraCare Group (effective September 23, 2025) and Citieffe Group (effective November 07, 2025). These strategic acquisitions are integral to the company’s roadmap for future growth in high-end technology segments such as cardiology and orthopedics. Management emphasized that while these acquisitions impacted short-term margins due to one-time regulatory and employee costs, they strengthen the firm’s competitive positioning in international markets.
Innovation and Operational Milestones
Innovation remains a core growth driver, with the company launching 35 new products during FY26 and maintaining a robust R&D team of approximately 90 professionals across India, Italy, and the Netherlands. The company’s focus on clinical engagement continues to yield results, with over 4,000 annual customer engagement programs conducted globally. Key operational successes include surpassing 11,000 units in cumulative stent deployments and achieving a total installed base of approximately 1,000 dialysis machines.
Future Outlook and Sustainability
Looking ahead, Poly Medicure remains committed to its strategy of import substitution in India and expansion in key international markets like the US and Europe. The company is doubling down on its R&D investments, which are expected to rise significantly in the next 3-5 years. Furthermore, sustainability is a key differentiator, with ~70% of facilities now ISO 14001:2015 certified and an ongoing push to increase solar energy capacity to further reduce scope 2 emissions.
Source: BSE
